140 related articles for article (PubMed ID: 12552981)
21. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
22. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
Cohen AD; Gopas J; Karplus G; Cohen Y
Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
[TBL] [Abstract][Full Text] [Related]
23. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study.
Bhatavdekar JM; Patel DD; Vora HH; Balar DB
Anticancer Res; 1993; 13(1):237-40. PubMed ID: 7682801
[TBL] [Abstract][Full Text] [Related]
24. [Role of tissue polypeptide antigen as a marker in bladder cancer].
Menéndez V; Filella X; Alcover J; Molina R; Ballesta AM; Carretero P
Actas Urol Esp; 1995 Jun; 19(6):441-4. PubMed ID: 8571803
[TBL] [Abstract][Full Text] [Related]
25. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
26. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
28. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer.
Senga Y; Kimura G; Hattori T; Yoshida K
Urology; 1996 Nov; 48(5):703-10. PubMed ID: 8911513
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
30. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
31. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
Luo RC; He XB; Cai HB; Li AM
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
[TBL] [Abstract][Full Text] [Related]
32. Increased urinary levels of tissue polypeptide specific antigen (TPS) in alcoholics.
Barros P; Gonzalez-Quintela A; Mella C; Perez LF
Anticancer Res; 2006; 26(2B):1531-4. PubMed ID: 16619568
[TBL] [Abstract][Full Text] [Related]
33. Tissue polypeptide-specific antigen (TPS) in pediatric malignancies.
Rebhandl W; Paya K; Felberbauer FX; Fuchs R; Henkel J; Bieglmayer C; Horcher E
Anticancer Res; 1997; 17(4B):2865-8. PubMed ID: 9329549
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
35. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer.
Mishaeli M; Klein B; Sadikov E; Bayer I; Koren R; Gal R; Rakowsky E; Levin I; Kfir B; Schachter J; Klein T
Anticancer Res; 1998; 18(3B):2101-5. PubMed ID: 9677475
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of bladder cancer by analysis of urinary fibronectin.
Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
[TBL] [Abstract][Full Text] [Related]
37. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
38. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
39. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L
Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Anticancer Res; 2000; 20(6D):5107-8. PubMed ID: 11326677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]